Borrowed from Ozequities............ A Reader, to whom grateful thanks, worked out the notional value of Life Therapeutics following its recent announcements which is significantly ahead of the share price. Life Therapeutics previously announced deal to sell its US plasma collection centres to Italian company Kedrion SpA in return for 11.5 pct of Kedrion which is expected to list via an IPO in 2008 valued at $US850 million according to LFE means that LFE's holding in Kedrion would be worth $US98 million in the IPO. LFE has now placed a valuation on the balance of its assets less debt of $US123 million or $A145 million. The Reader points out, "There are currently 108 million LFE shares on issue. Therefore, value per share equates to $A1.34 based on LFE's own numbers. The Plasma industry is currently very sexy with strong global growth in demand and prices, so LFE should be able to achieve attractive prices for their assets by selling into this strong market for plasma".
LFE
life therapeutics limited
